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Comparison of radiomic feature 
aggregation methods for patients 
with multiple tumors
Enoch Chang1, Marina Z. Joel1, Hannah Y. Chang2, Justin Du3, Omaditya Khanna4, 
Antonio Omuro5, Veronica Chiang6 & Sanjay Aneja1,5,7*
Radiomic feature analysis has been shown to be effective at analyzing diagnostic images to 
model cancer outcomes. It has not yet been established how to best combine radiomic features in 
cancer patients with multifocal tumors. As the number of patients with multifocal metastatic cancer 
continues to rise, there is a need for improving personalized patient-level prognosis to better inform 
treatment. We compared six mathematical methods of combining radiomic features of 3,596 tumors 
in 831 patients with multiple brain metastases and evaluated the performance of these aggregation 
methods using three survival models: a standard Cox proportional hazards model, a Cox proportional 
hazards model with LASSO regression, and a random survival forest. Across all three survival models, 
the weighted average of the largest three metastases had the highest concordance index (95% 
confidence interval) of 0.627 (0.595–0.661) for the Cox proportional hazards model, 0.628 (0.591–
0.666) for the Cox proportional hazards model with LASSO regression, and 0.652 (0.565–0.727) for 
the random survival forest model. This finding was consistent when evaluating patients with different 
numbers of brain metastases and different tumor volumes. Radiomic features can be effectively 
combined to estimate patient-level outcomes in patients with multifocal brain metastases. Future 
studies are needed to confirm that the volume-weighted average of the largest three tumors is an 
effective method for combining radiomic features across other imaging modalities and tumor types.
Recent advances in machine learning and diagnostic imaging have increased enthusiasm surrounding the use 
of quantitative imaging to model clinical outcomes. One quantitative imaging technique that holds particular 
promise in modeling cancer outcomes is radiomic feature analysis. Radiomic features are quantitative metrics of 
size, shape, intensity, and texture that are extracted from medical images using high-throughput computational 
mining  techniques1,2. These features represent unique radiographic signatures that have been shown to reveal 
prognostic insights about underlying gene-expression  patterns3 and treatment  response4 that may not be visible 
to the human eye.
Although radiomic features have shown the ability to risk stratify cancer  patients5,6, radiomic analysis has 
largely been limited to the evaluation of individual tumor volumes. There is no established methodology regard-
ing the best way to combine radiomic features for patients with multifocal sites of disease to establish a patient-
level correlate of clinical outcomes. Within oncology, estimating patient outcomes among patients with multiple 
sites of metastatic disease is of particular interest as it influences multi-disciplinary treatment paradigms.
Prognostication for patients with metastatic disease is an area of increasing need, given as many as 49% of 
lung cancer patients within the United States are diagnosed with metastatic disease upon initial  presentation7. 
More importantly, nearly 75% of patients with metastatic disease have greater than 5 lesions at  diagnosis8. Even 
among non-metastatic cancer patients, as many as 17% of patients have multi-focal primary  tumors9. Brain 
metastases represent a significant proportion of metastatic cancer patients, and conservatively, at least 50% of 
patients diagnosed with metastatic brain disease have multiple brain  lesions10. With improved MRI brain imag-
ing, it is likely that the number of patients found with multiple metastases is even  higher11.
In this study, we attempted to identify optimal techniques to combine radiomic features for patients with mul-
tiple brain metastases to model patient-level outcomes. We compared various methods of combining radiomic 
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features of individual tumors in patients with multiple brain metastases and evaluated the performance of dif-
ferent radiomic aggregation methods in estimating survival in patients using several different survival models.
Results
Patient demographics. A total of 831 patients with 3596 brain metastases were included. Patient demo-
graphics are presented in Table 1. Median overall survival was 12 months, median follow-up was 36 months, and 
257 patients were right-censored. Median age was 63 years, and the most common primary malignancies were 
NSCLC (41.0%), melanoma (17.3%), breast (13.1%), SCLC (6.6%), renal (5.9%), and GI (5.3%). 543 patients 
(65.3%) had < 5 metastases, 214 (25.8%) had 5–10 metastases, and 74 (8.9%) had 11 + metastases.
Overall results. Table 2 presents a comparison of various aggregation methods across several survival mod-
els.
For the standard Cox proportional hazards model, the weighted average of the largest three metastases had 
the highest C-index (95% confidence interval) of 0.627 (0.595–0.661). The weighted average of the largest three 
metastases also had the highest C-index of all the aggregation methods on the Cox proportional hazards model 
with LASSO regression with a C-index of 0.628 (0.591–0.666) and on the random survival forest with a C-index 
of 0.652 (0.565–0.727).
Sub-analysis: number of metastases. Table 3 presents model performance of sub-analyses based on 
number of brain metastases. For patients with < 5 metastases, the weighted average of their 3 largest metastases 
had the highest C-index on the standard Cox proportional hazards model with a C-index of 0.640 (0.600–0.686). 
For patients with 5–10 metastases, the unweighted average of all their metastases had the highest C-index of 
0.697 (0.638–0.762). For patients with 11 + metastases, the model including only data from the largest metastasis 
as well as the number of metastases performed with the highest C-index of 0.909 (0.803–0.993).
Sub-analysis: volume of largest metastasis. Table  4 describes model performance of sub-analyses 
based on volume of the largest metastasis. Across all sub-groups, the weighted average of the largest three 
metastases had the highest C-indices of 0.701 (0.652–0.748), 0.687 (0.622–0.728), 0.679 (0.623–0.733) for vol-
umes < 0.200 cc, 0.200–0.700 cc, and > 0.700 + cc, respectively.
Table 1.  Patient demographics. * If available.
Age
< 50 121 (14.6%)
50–59 199 (23.9%)
60–69 282 (33.9%)










< 5 543 (65.3%)
5–10 214 (25.8%)
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Sensitivity analysis. Model performance was not improved when using the weighted average of the largest 
2 and largest 4 metastases across survival models (Supplement 3). Model performance was lower when using 
PCA rather than mRMR for feature selection (Supplement 4). The Cox proportional hazards models with LASSO 
regression and random survival forest models using all 851 radiomic features did not have higher c-indices com-
pared to models with prior feature selection – notably, the models using the weighted average of the largest three 
metastases continued to perform best (Supplement 5).
Table 2.  Comparison of aggregation methods.
Model C-Index (95% CI)
Cox proportional hazards
Unweighted average 0.610 (0.570–0.646)
Weighted average 0.604 (0.571–0.641)
Weighted average of largest 3 metastases 0.627 (0.595–0.661)
Largest + number of metastases 0.612 (0.579–0.649)
Largest metastasis 0.598 (0.559–0.636)
Smallest metastasis 0.595 (0.567–0.631)
Cox proportional hazards with LASSO regression
Unweighted average 0.612 (0.585–0.647)
Weighted average 0.603 (0.573–0.640)
Weighted average of largest 3 metastases 0.628 (0.591–0.666)
Largest + number of metastases 0.597 (0.560–0.632)
Largest metastasis 0.596 (0.562–0.630)
Smallest metastasis 0.597 (0.557–0.630)
Random survival forest
Unweighted average 0.649 (0.548–0.709)
Weighted average 0.641 (0.567–0.729)
Weighted average of largest 3 metastases 0.652 (0.565–0.727)
Largest + Number of metastases 0.622 (0.542–0.706)
Largest metastasis 0.627 (0.544–0.694)
Smallest metastasis 0.621 (0.529–0.709)
Table 3.  Sub-Analysis: Number of Metastases. *** Collinear.
Model C-Index (95% CI)
< 5 Metastases (n = 543)
Unweighted average 0.621 (0.583–0.661)
Weighted average 0.617 (0.570–0.651)
Weighted average of largest 3 metastases 0.640 (0.600–0.686)
Largest + number of metastases 0.639 (0.593–0.676)
Largest metastasis 0.619 (0.580–0.653)
Smallest metastasis 0.612 (0.566–0.655)
5–10 Metastases (n = 214)
Unweighted average 0.697 (0.638–0.762)
Weighted average 0.682 (0.617–0.743)
Weighted average of largest 3 metastases 0.688 (0.635–0.749)
Largest + number of metastases 0.691 (0.634–0.750)
Largest metastasis 0.688 (0.623–0.740)
Smallest metastasis ***
11 + metastases (n = 74)
Unweighted average 0.876 (0.776–0.964)
Weighted average 0.872 (0.771–0.965)
Weighted average of largest 3 metastases 0.880 (0.787–0.964)
Largest + number of metastases 0.909 (0.803–0.993)
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Discussion
The emerging field of radiomic feature analysis has shown particular promise in cancer research. However, tradi-
tional radiomic feature analysis has had limited utility for patients with metastatic or multifocal disease because 
there is a paucity of established methods which aggregate radiomic features across multiple tumors to establish 
patient-level outcome estimates. Given the majority of cancer patients with brain metastases have multifocal 
disease, they represent an optimal patient population to study this question. We compared different methods of 
aggregating radiomic features and tested their performance across different survival models. Our study suggests 
that a volume-weighted average of the radiomic features of the largest three brain metastases is the most effec-
tive technique to model survival across various methods of survival analysis. Furthermore, this suggests that in 
patients with multi-focal disease, the largest tumors may be driving prognosis.
Practical implications of these findings include more efficient computational and clinical resource utiliza-
tion. As server costs, data storage requirements, and computation time increase with increasing dataset size and 
complexity, effective models of prognosis may potentially be developed with just the data from the largest three 
metastases alone. Furthermore, clinicians may save time by only needing to manually segment the largest three 
metastases.
This study corroborates studies that have found radiomic features to correlate with prognosis among  lung12, 
 breast13, and prostate cancer  patients6. To address the issue of combining multi-focal data at a patient-level, prior 
studies have implemented a weighted average of features of all  metastases14 while others have included all tumors 
from a specific patient assigned to either a training or validation set to avoid cluster-correlation  biases15. While 
tumor-level data may be useful for certain tasks like primary-site prediction, there is a need for aggregation of 
patient-level data for overall outcomes like survival or recurrence.
A notable finding of this study is that across all models, it was important that some measure of multi-focality 
was incorporated, whether aggregating radiomic features from the largest three metastases or including a clinical 
measure of multi-focality in the number of metastases.
On sub-analysis, across all volume groups of the largest metastasis, the weighted average of the largest three 
tumors had the highest performance. As the number of metastases increased greater than 5, models incorporat-
ing radiomic data from the largest metastasis with the addition of the number of metastases performed better, 
suggesting that with a higher number of metastases, additional non-imaging data (i.e. clinical data) may improve 
model performance, as prior studies have demonstrated the promise of clinical data alone in modeling  survival16. 
Future studies are planned to incorporate both imaging and clinical data variables.
This study has limitations. First, there is an inherent selection bias since all the patients in this study were 
limited to those with brain metastases so results may vary across other disease sites. Second, these patients were 
all treated at one institution with the same MRI protocol. Efforts are underway to validate these findings at an 
independent institution. Third, these patients were ultimately treated with the same treatment modality. Further 
analysis is needed for patients treated with different interventions.
In conclusion, this study suggests that radiomic features can be effectively combined to establish patient-level 
outcomes in patients with multifocal disease. Future studies are needed to confirm that the volume-weighted 
Table 4.  Sub-analysis: volume of largest metastasis. ***Collinear.
Model C-Index (95% CI)
Largest metastasis < 0.200 cc (n = 261)
Unweighted average 0.674 (0.630–0.729)
Weighted average 0.694 (0.639–0.749)
Weighted average of largest 3 0.701 (0.652–0.748)
Largest + number of metastases 0.698 (0.644–0.767)
Largest 0.695 (0.634–0.736)
Smallest ***
Largest metastasis 0.200–0.700 cc (n = 281)
Unweighted Average 0.663 (0.615–0.719)
Weighted average 0.675 (0.622–0.731)
Weighted average of largest 3 0.687 (0.622–0.728)
Largest + number of metastases 0.668 (0.621–0.727)
Largest 0.656 (0.611–0.717)
Smallest ***
Top 20 features largest metastasis 0.700 + cc (n = 289)
Unweighted average 0.671 (0.616–0.717)
Weighted average 0.656 (0.602–0.718)
Weighted average of largest 3 0.679 (0.623–0.733)
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average of the largest three tumors is an effective method for combining radiomic features across other imaging 
modalities and disease sites.
Methods
Patient data. Research was conducted in accordance with the Declaration of Helsinki guidelines and 
approved by the Yale University Institutional Review Board. Informed consent was obtained from all partici-
pants in this study. We analyzed 831 patients with 3,596 brain metastases treated with primary stereotactic 
radiosurgery (SRS) at our institution between 2000 and 2018. Patients with prior resection or prior radiation 
treatment were excluded. Metastases < 5 mm were also excluded. The primary outcome of interest was overall 
survival following SRS treatment defined as time from SRS treatment date to date of death or last follow-up.
Image preprocessing. The image preprocessing workflow is illustrated in Fig.  1. Individual metastases 
were segmented on T1-weighted contrast enhanced MRI images and approved by both a radiation oncologist 
and a neurosurgeon. A bounding box with 1 mm of peri-tumoral tissue around the maximum dimension of the 
tumor contour in the axial plane was created to ensure edge detection of the tumor. Images were resampled to 
1 mm pixel spacing, corrected for low frequency intensity non-uniformity present in MRI data with the N4ITK 
bias field correction  algorithm17, and z-score normalized to reduce inter-scan bias.
Radiomic feature extraction and aggregation. 851 radiomic  features2 (Supplement 1) were extracted 
from the processed images of each brain metastasis and analyzed as predictors of survival. The following aggrega-
tion methods were compared to estimate patient-level risk for patients with multiple metastases: (1) Unweighted 
Average: Radiomic size and shape features were summed while all other features were averaged for each patient. 
(2) Weighted Average: Radiomic size and shape features were summed while all other features were averaged for 
each patient based on a weighted proportion of total volume of all metastases per  patient14. (3) Weighted Average 
of Largest Three Metastases: Radiomic size and shape features from the largest three metastases of each patient 
were summed while all other features from the largest three metastases were averaged based on a weighted pro-
portion of the total volume of the largest three metastases. The largest three metastases were chosen since the 
Graded Prognostic Assessment, a widely accepted model for prognostication, uses a cut-off of three metastases 
for prognostic risk  stratification16. (4) Largest Metastasis + Number of Metastases: The features from the largest 
metastasis of each patient were selected, and the total number of metastases for each patient was included as an 
additional  variable16. (5) Largest Metastasis Alone. (6) Smallest Metastasis Alone as a control with the assump-
tion that the smallest tumor would have decreased prognostic value compared to larger tumors.
Statistical analysis and survival models. The following survival models were tested: a traditional Cox 
proportional hazards  model18, a Cox proportional hazards model with LASSO (least absolute shrinkage and 
selection operator)  regression19, and a random survival  forest20. Dimensionality reduction was performed at 
the patient level after radiomic feature aggregation. The top 20 ranked features (Supplement 2) were selected 
via minimum redundancy maximum relevance (mRMR)21, a method shown in multiple prior publications to 
effectively reduce dimensionality of radiomic features while maintaining the most relevant features for cancer 
 prognostication12,22,23. Hyperparameter tuning for the Cox proportional hazards model with LASSO regression 
and the random survival forest model was performed with fivefold cross-validation using a grid search. Discrim-
inatory ability of each model was assessed with calculated concordance indices (c-index) using 100 bootstrapped 
samples of 416 patients (50%). Multiple survival models were assessed to determine if particular aggregation 
methods were superior for specific survival models.
Sub-group analysis. A sub-group analysis was performed to evaluate the role of the following potential 
drivers of patient prognosis: the overall number of  metastases16 and the volume of the largest metastasis of each 
 patient24. The robustness of the various radiomic aggregation techniques was evaluated by comparing the Cox 
Figure 1.  Preprocessing Workflow. (a) Input: slices of pre-treatment T1-post contrast brain MRI scans. (b) 
Identification of the region of interest from manual segmentations. (c) Output: extracted tumors with pixel 
resampling, N4ITK bias field correction, and z-score normalization.
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proportional hazards model across these sub-groups: the number of metastases (< 5 metastases, 5–10 metasta-
ses, 11 + metastases) as well as the volume of the largest metastasis (< 0.200 cc, 0.200–0.700 cc, > 0.700 + cc) per 
patient.
Sensitivity analysis. A sensitivity analysis was performed to compare the weighted average of the largest 
2 and largest 4 metastases across survival models. Additionally, a sensitivity analysis was performed for the Cox 
proportional hazards models across aggregation methods using Principal Component Analysis (PCA) at the 
patient level post-aggregation to select a minimum number of features such that 90% of variance was retained. 
Finally, another analysis was performed where all 851 radiomic features were used for the Cox proportional 
hazards models with LASSO regression and the random survival forest models.
Code availability
Radiomic features were extracted using PyRadiomics (version 2.2.0)25. Minimum redundancy maximum rel-
evance feature selection was performed with the mRMRe package using R version 3.6.226. Principal component 
analysis was performed with the scikit-learn  package27. Image preprocessing and comparison of aggregation 
were performed with Python version 3.7. Survival analysis was performed with the lifelines and scikit-survival 
 packages28. Code to reproduce our analysis is available at https:// github. com/ Aneja- Lab- Yale/ Aneja- Lab- Public- 
Brain MetsR adiom ics.
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